NEOGEN CORP (NEOG)
NEOGEN CORP (NEOG) from its SEC filings: 2025 revenue $870.4 million (-3% vs the year before), net margin -1%, free cash flow $83.2 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Revenue (2025) | $870.4 million |
| Revenue growth | -3% |
| Net income | -$7.9 million |
| Net margin | -0.9% |
| Free cash flow | $83.2 million |
| Diluted EPS | $-0.04 |
| Latest quarter (Q3 2026 (calendar)) revenue vs a year earlier | +6% |
| Cash | $172.0 million |
| Long-term debt | $774.2 million |
| Share count, 1 year | +0% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.